

Spanish biotechnology company offers first-in-class microbiota based therapeutic to restore gut microbiome balance for severe infections and chronic diseases

Summary

Profile type

Technology offer

Company's country

Spain

POD reference

TOES20250916012

Profile status

PUBLISHED

Type of partnership

Commercial agreement with technical assistance
Investment agreement

Targeted countries

• World

Contact Person

[Enrico FRANZIN](#)

Term of validity

16 Sep 2025
16 Sep 2026

Last update

18 Sep 2025

General Information

Short summary

Spanish biotechnology company dedicated to the research, development and GMP-certified production of intestinal microbiota-based therapies. The proprietary technology FSPIM® (Full Spectrum Purified Intestinal Microbiota) enables the formulation of full-spectrum oral capsules that restore gut microbiome balance in dysbiosis-related diseases. Seeking strategic investors and commercial agreement with technical assistance to support industrial scale-up and international commercialization.

Full description

The organization is an innovative Spanish biotechnology company dedicated to the research, development, and GMP-certified production of therapies based on intestinal microbiota. Its proprietary technology, FSPIM® (Full Spectrum Purified Intestinal Microbiota), enables the formulation of oral capsules designed to restore gut microbiome balance in patients with recurrent Clostridioides difficile infection, diverticulitis, and decompensated liver cirrhosis.

This full-spectrum approach provides a safe, effective, and minimally invasive alternative to conventional antibiotics and unregulated fecal microbiota transplants. Produced under strict GMP standards, the capsules ensure stability, reproducibility, and patient compliance while maintaining the complexity of the native microbiota.

The business model is based on the industrial manufacturing and supply of finished products under rigorous quality and safety controls, while collaborating with pharmaceutical distributors, healthcare organizations, and strategic investors to support industrial scale-up, international commercialization, and the development of new clinical applications

Advantages and innovations

First full-spectrum microbiota-based solution produced under GMP standards in Europe, combining industrial scalability with clinical robustness. The proprietary FSPIM® technology preserves the diversity and functionality of the intestinal microbiota, ensuring reproducibility and long-term stability through a patented process protected by trade secrets and blockchain-certified traceability.

The therapy has been clinically validated in a Phase III trial for recurrent *Clostridioides difficile* infection (CDI), showing high efficacy and an excellent safety profile. In addition, it has demonstrated positive outcomes in a compassionate use program in more than 100 patients, reinforcing its real-world evidence base. Ongoing clinical trials are extending the scope to recurrent diverticulitis and decompensated liver cirrhosis, addressing major unmet medical needs.

The oral capsule format with controlled release provides a minimally invasive, patient-friendly alternative to antibiotics or unregulated fecal microbiota transplants, with 100% patient adherence observed. Stakeholders have highlighted the strong clinical value of this approach, particularly its role in reducing recurrences, hospital burden and invasive procedures.

This solution represents a disruptive, sustainable and scalable therapeutic platform: safer than FMT (Fecal Microbiota Transplant), more effective than antibiotics, and aligned with healthcare demand for innovative, standardized and clinically impactful treatments.

Technical specification or expertise sought

Ideal partners are organizations with strong expertise in healthcare or biotechnology, established networks in hospital and outpatient channels, and proven capacity to manage innovative therapy distribution.

Stage of development

Available for demonstration

IPR Status

IPR applied but not yet granted

IPR Notes

Process patent application filed and trade secrets protected through blockchain-certified protocols; FSPIM® trademark registered in the EU.

Sustainable Development goals

• **Goal 3: Good Health and Well-being**

Partner Sought

Expected role of the partner

The partner is expected to engage in commercial agreements and distribution to expand patient access. This may include exclusive supply and distribution arrangements, support for local market access, and technical assistance to ensure compliance with quality, traceability and safety requirements.

Strategic investors are also sought to contribute to industrial scale-up and international expansion.

Type of partnership

Commercial agreement with technical assistance

Investment agreement

Type and size of the partner

- **Other**
- **R&D Institution**
- **SME 50 - 249**
- **University**

Dissemination

Technology keywords

- **06001012 - Medical Research**
- **06001002 - Clinical Research, Trials**

Targeted countries

- **World**

Market keywords

- **04009 - In vitro Testing, Trials**
- **04010 - Microbiology**
- **04005 - Biochemistry / Biophysics**

Sector groups involved

- **Health**